Fig. 7

The ability of HMRs model to predict the outcome of liver cancer treatment A Association between risk scores and immunotherapy response based on the IMvigor210. B Difference in response to immunotherapy in risk groups predicted by TIDE. Differences in the TIS C IPS D IPS-CTLA4- and PD1/PDL1/PDL2 blocker E IPS-CTLA4 blocker F, IPS-PD1/PDL1/PDL2 blocker G ICIs H and HLA I between two groups. J Association between risk scores and TACE treatment response. K Difference in IC50 of common chemotherapy drugs between risk group. The significance of the difference was analyzed by Wilcoxon signed rank test. (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, NS means non-significant)